Use of Glucagon-Like Peptide-1 Receptor Agonists and Risk of Parkinson's Disease: Scandinavian Cohort Study.
Use of Glucagon-Like Peptide-1 Receptor Agonists and Risk of Parkinson's Disease: Scandinavian Cohort Study.
Where did the research take place?
The study site has not been established. Author addresses may differ from where the research occurred.
Solna, SE · Author affiliation
Clinical Epidemiology Division, Department of Medicine, Centre for Pharmacoepidemiology, Solna, Karolinska Institutet, Stockholm, Sweden.Location evidence
Stockholm, SE · Author affiliation
Clinical Epidemiology Division, Department of Medicine, Centre for Pharmacoepidemiology, Solna, Karolinska Institutet, Stockholm, Sweden.Location evidence
Copenhagen, DK · Author affiliation
Department of Epidemiology Research, Statens Serum Institut, Copenhagen, Denmark.Location evidence
Gothenburg, SE · Author affiliation
Department of Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden.Location evidence
Trondheim, NO · Author affiliation
Department of Public Health and Nursing, Faculty of Medicine and Health Science, HUNT Center for Molecular and Clinical Epidemiology, NTNU-Norwegian University of Science and Technology, Trondheim, Norway.Location evidence
Levanger, NO · Author affiliation
Faculty of Medicine, HUNT Research Center, NTNU-Norwegian University of Science and Technology, Levanger, Norway.Location evidence
US · Author affiliation · country only
Department of Pediatrics, Stanford University School of Medicine, Stanford, California, USA.Location evidence
A plain-language reading has not been prepared for this paper yet.
Original abstract
AIMS: To investigate the association between use of GLP-1 receptor agonists and incident Parkinson's disease. MATERIAL AND METHODS: Cohort study using data from nationwide registers in Denmark, Norway and Sweden and an active-comparator, new-user design. We included 158 961 new users of GLP-1 receptor agonists and 188 065 new users of sulfonylureas, aged 45 years or older. Liraglutide accounted for 72.9% of GLP-1 receptor agonist follow-up time, followed by semaglutide (13.4%), exenatide (7.3%), dulaglutide (5.1%) and lixisenatide (1.3%). The primary outcome was incident Parkinson's disease, defined as a first-ever diagnosis of Parkinson's disease (ICD-10 G20) or Parkinson's disease dementia (ICD-10 F02.3) in national patient registers. Cox regression with propensity score weighting was used to estimate hazard ratios (HRs) and control for confounding. RESULTS: Mean age was 65 years and 43% were female. Incidence rates for Parkinson's disease were 5.2 and 8.0 per 10 000 person-years among GLP-1 receptor agonist and sulfonylurea users, respectively (adjusted HR 0.81 [95% CI 0.68-0.96]). Results were consistent in a 2-year lag-time analysis (HR 0.84 [95% CI 0.70-1.02]) after excluding or censoring users of DPP-4 inhibitors at cohort entry or during follow-up (HR 0.74 [95% CI 0.60-0.93]) and in subgroup analyses by sex and age. CONCLUSION: In this large observational cohort study, use of GLP-1 receptor agonists compared with sulfonylureas was associated with a lower risk of incident Parkinson's disease. These findings support a potential neuroprotective role of GLP-1 receptor agonists, though replication in additional studies is needed.